Borrador de trabajo. Versión (8 Mayo 2007)




descargar 232.26 Kb.
títuloBorrador de trabajo. Versión (8 Mayo 2007)
página5/5
fecha de publicación17.01.2016
tamaño232.26 Kb.
tipoDocumentos
b.se-todo.com > Documentos > Documentos
1   2   3   4   5

13 - BIBLIOGRAFÍA
Artículos de revisión, guías clínicas y boletines independientes empleados en la elaboración de este tema de la Guía Interniveles de Baleares


  • Guia Clínica Nº1: Diabetes. Gerencia de Atención Primaria de Mallorca, 2004

  • American Diabetes Association (ADA). Standards of medical care in diabetes. V. Diabetes care. Diabetes Care 2006 Jan; 29(Suppl 1):S8-17.

  • Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Disponible en: Eur Heart J doi:10.1093/eurheartj/ehl260.

  • Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care IDF Clinical Guidelines Task Force. Diabet. Med. 2006; 23: 579–593 .

  • Adult diabetes clinical practice guidelines. National Guideline Clearinghouse.

  • Boletín de información farmacoterapéutica de Euskadi. Actualización en insulinas VOLUMEN 13 - Nº 3 / MARZO 2005.

  • Boletín terapéutico CADIME: Nuevas insulinas Año 2006, Volumen 22 nº 5.

  • Butlletí groc: Análogos de insulina. Mayo-Junio 2006, Vol 19, nº3

  • Boletín de información terapéutica de Navarra Rosiglitazona y pioglitazona. Evaluación crítica de los ensayos PROactive y DREAM VOLUMEN 15, Nº 2 MARZO 2007.

  • Management of diabetes. Quick Reference Guide. SIGN November 2001.

  • Boletín de información farmacoterapéutica de Euskadi. Glitazonas en diabetes mellitus tipo 2 VOLUMEN 14 - Nº 3 / MARZO 2006.

  • Boletín terapéutico CADIME: Papel de las tiazolidindionas (rosiglitazona y pioglitazona) en el tratamiento de la DM2: puesta al día Año 2004, Volumen nº 4.

  • Boletín terapéutico CADIME: Rosiglitazona/Metformina Año 2005, nº 5.

  • Boletín terapéutico CEVIME: Rosiglitazona/Metformina Año 2006. Volumen 108

  • Tratamiento farmacológico de la diabetes mellitus tipo 2. Grupo de diabetes de la SAMFyC. Marzo 2007.



Referencias bibliográficas

1 K.G.MM. Alberti, P Zimmet, J. Shaw. International Diabetes federation: a consensus on Type 2 diabetes prevention. Diabetic Medicine 2007; 24:451-463

2 Nathan DM; Buse JB; Davidson MB; Heine RJ; Holman RR; Sherwin R; Zinman B. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006 Aug;29(8):1963-72.

3 United Kingdom Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 1998; 352:854-865

4 Hermann LS; Schersten B; Bitzen PO; Kjellstrom T; Lindgarde F; Melander A Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study Diabetes Care 1994 Oct;17(10):1100-9.

5 DeFronzo RA; Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995 Aug 31;333(9):541-9

6 Fonseca V; Rosenstock J; Patwardhan R; Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000 Apr 5;283(13):1695-702.

7 Goudswaard AN, Furlong NJ, Rutten GEHM, Stolk RP, Valk GD. Monoterapia con insulina versus combinaciones de insulina con agentes hipoglucemiantes orales para pacientes con diabetes mellitus tipo 2 (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, número 1, 2007. Oxford, Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2007 Issue 1. Chichester, UK: John Wiley & Sons, Ltd.).

8 Moses R; Slobodniuk R; Boyages S; Colagiuri S; Kidson W; Carter J; Donnelly T; Moffitt P; Hopkins H . Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999 Jan;22(1):119-24.

9 Horton ES; Clinkingbeard C; Gatlin M; Foley J; Mallows S; Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000 Nov;23(11):1660-5.

10 A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 1999 Mar;22(3):463-7.

11 Kipnes, MS, Krosnick, A, Rendell, MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001; 111:10

12 A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 1999 Mar;22(3):463-7.

13 Hollander PA; Schwartz SL; Gatlin MR; Haas SJ; Zheng H; Foley JE; Dunning BE. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001 Jun;24(6):983-8.

14 Gribble FM; Manley SE; Levy JC. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166) Diabetes Care 2001 Jul;24(7):1221-5.

15 Repaglinide plus metformin combination more effective than nateglinide plus metformin for type 2 diabetes? Diabetes Care 2003; 26:2063-2068

16 United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995 Jan 14;310(6972):83-8

17 Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D.. Monoterapia con metformina para la diabetes mellitus tipo 2 (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, número 1, 2007. Oxford, Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2007 Issue 1. Chichester, UK: John Wiley & Sons, Ltd.).

18 Prescrire Rédaction. Pioglitazone – Actosº, rosiglitazone – Avandiaº en monothérapiede deuxième ligne: non justifiée par l’évaluation clinique. RevPrescrire. 2005;25(259):175-9.

19 Prescrire Rédaction. Pioglitazone – Actosº, rosiglitazone – Avandiaº, rosiglitazone+ metformine - Avandametº. Glitazone + antidiabétique oral: des associationsencore trop peu évaluées. Rev Prescrire. 2005;25(260):245-53.

20 Czoski-Murray C, Warren E, Chilcott J, Beverly C, Psyllaki MA, Cowan J.Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazonein the treatment of type 2 diabetes: a systematic review and economic evaluation.Health Technol Assess. 2004;8(13)

21 Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M. Efficacy andsafety of pioglitazone versus metformin in patients with type 2 diabetesmellitus: a double-blind, randomized trial. J Clin Endocrinol Metab.2004;89:6068-76.

22 Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Longterm therapy with addition of pioglitazone to metformin compared with theaddition of gliclazide to metformin in patients with type 2 diabetes: a randomized,comparative study. Diabetes Metab Res Rev. 2005;21:167-74.

23 Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH,Hanefeld M. Long-tem efficacy and tolerability of add-on pioglitazone therapyto failing monotherapy compared with addition of gliclazide or metformin inpatients with type 2 diabetes. Diabetologia. 2005;48:1093-1104.

24 Aronoff S; Rosenblatt S; Braithwaite S; Egan JW; Mathisen AL; Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000 Nov;23(11):1605-11.

25 Lebovitz HE; Dole JF; Patwardhan R; Rappaport EB; Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001 Jan;86(1):280-8.

26 Phillips LS; Grunberger G; Miller E; Patwardhan R; Rappaport EB; Salzman A Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001 Feb;24(2):308-15.

27Chiquette, E, Ramirez, G, Defronzo, R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164:2097.

28 Goldberg, RB, Kendall, DM, Deeg, MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28:1547

29 Rosiglitazone (Avandia®), pioglitazone (Actos®). Deux nouveaux antidiabétiques oraux trop peu évalues. Rev Presc 2002 ; 22(231): 569- 77

30 Alerta de farmacovigilancia de la AEMPS, sobre rosiglitazona y pioglitazona : incremento de riesgo de fracturas en mujeres. Nota informativa 05/2007. Disponible en: http://www.agemed.es/actividad/alertas/usoHumano/seguridad/rosiglitazona.htm

31 Dormandy JA, Charbonnel B, Eckland DA, Erdmann E, Massi-Benedetti M, Moules IK et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a rancomised controlled trial. Lancet 2005; 366: 1279-89.

32 Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A on behalf of the PROactive Study Group. The prospective pioglitzone clinical trial in macrovascular events (PROactive): can pioglitazione reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004; 27: 1647-1653.

33 The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-1105.

34 The DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004; 47: 1519-1527.

35 Home, PD, Pocock, SJ, Beck-Nielsen, H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005; 48:1726

36 Henry J. Dargie, MBCHB,* Per R. Hildebrandt, MD,† Günter A. J. Riegger, MD,‡ John J. V. McMurray, MD,* Stephen O. McMorn, PHD,§ Jeremy N. Roberts, MSC,_ Andrew Zambanini, MRCP,§ John P. H. Wilding, DM. A Randomized, Placebo-Controlled Trial Assessing the Effects of Rosiglitazone on Echocardiographic Function and Cardiac Status in Type 2

Diabetic Patients With New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol 2007;49:1696–704


37 Van de Laar FA, Lucassen PLBJ, Akkermans RP, Van de Lisdonk EH, Rutten GEHM, Van Weel C. Inhibidores de la alfaglucosidasa para la diabetes mellitus tipo 2 (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, número 1, 2007. Oxford, Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2007 Issue 1. Chichester, UK: John Wiley & Sons, Ltd.).

38 van de Laar FA; Lucassen PL; Akkermans RP; van de Lisdonk EH; Rutten GE; van Weel C. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005 Jan;28(1):154-63.

39 Ryan GJ, Jobe LJ, Martin R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.Clin Ther. 2005 Oct;27(10):1500-12

40 Exenatide disponible en :

http://www.pcpoh.bham.ac.uk/publichealth/horizon/PDF_files/2005reports/Exenatide.pdf

41 Plank. Systematic review and meta-analysis of Short-Acting Insulin Analogues in Patients with Diabetes Mellitus. Arch Intern Med. 2005;165:1337-1344.

42 Hirsch. Drug therapy: Insulin Analogues. N Engl J Med 2005; 352:174-3.

43 Siebenhofer A, Plank J, Berghold A, Narath M, Gfrerer R, Pieber TR.Análogos de insulina de acción rápida versus insulina humana regular en pacientes con diabetes mellitus. En: La Cochrane Library plus en español. Oxford: Update Software.

44 BOT - Base de Datos del Medicamento. Consejo General de Colegios Oficiales de farmacéuticos ®, 2006 marzo.

45 Ficha técnica insulina glargina. sanofi aventis

46 Rosenstock J, Dailey G, Massi-Benedetti M et al. Reduced Hypoglycemia Risk With Insulin Glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005; 28: 950-955.

47 Rosentstock J et al Basal insulin glagine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000; Aug 23(8): 1137-1142

48 Pieber T R et al. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes Diabetes care 2000; feb 23 (2): 157-62

49 Home PD et al. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev 2005;21:545-553

50 Ratner R E et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes care 2000; may 23 (5): 639-643

51 Raskin P et al A 16 week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

Diabetes care 2000; Nov 23 (11): 1666-1671

52 Yi-Jarvinen H, Dressler A, Zieme M,Lss nocturnal hypoglycemia and better postdinner glucose control with bedtime glargine compared with bedtime NPH during insulin combination therapy in type 2 diabetes. Diabetes Care 2000; 23:1130-1136.

53 Riddle MC, Rossenstock J, Gerich J The treat-to target trial. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26:3080-3086

54 Fritsche A, Schweitzer MA, Haring HU, Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn Insulin or bedtime Insulin Glargine in patientes with type 2 Diabetes. Ann Intern med 2003;138:952-959

55 Rosenstock J, Schwartz SL, Clark CM, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes. Diabetes Care 2001; 24;631-636

56 Informe EMEA insulina glargina:

http://www.emea.europa.eu/humandocs/Humans/EPAR/lantus/lantus.htm

57 National Institute for Clinical Excellence. Guidance on the use of longactinginsulin analogues for the treatment of diabetes-insulin glargine. Technology Appraisal Guidance-Nº53. December 2002. Disponible en: http://www.nice.org.uk

58 Home P, Bartley P, Russell-Jones D et al. Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes. Diabetes Care 2004; 27: 1081-7.

59 Hermansen K, Davies M, Derezinski T et al. A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin Naïve People With Type 2 Diabetes. Diabetes Care 2006; 29: 1269-74.

60 Comité de Medicamentos de Uso Humano (CHMP). Informe Público Europeo de Evaluación (EPAR). Apidra®. DCI: Insulina glulisina. CPMP/1218/04.

61 Royle P, Waugh N, McAuley L, McIntyre L, Thomas S. Insulina inhaladapara la diabetes mellitus. En: La Cochrane Library plus en español. Oxford: Update software.



1   2   3   4   5

similar:

Borrador de trabajo. Versión (8 Mayo 2007) icon[borrador de propuesta de 46 puntos versióN 14 de enero de 2012]

Borrador de trabajo. Versión (8 Mayo 2007) iconBorrador versión Digital de la Guía Fitosanitaria casafe edición 2011

Borrador de trabajo. Versión (8 Mayo 2007) iconCurriculum vitae
«Codificación del Derecho internacional privado europeo», organizado por la Universidad Pompeu Fabra, Barcelona, el día 24 de mayo...

Borrador de trabajo. Versión (8 Mayo 2007) iconArchivo y borrador por Jacques Derrida1

Borrador de trabajo. Versión (8 Mayo 2007) iconPropuesta de programa de farmacologia I (pg-201), carrera de medicina (primer borrador)

Borrador de trabajo. Versión (8 Mayo 2007) iconA continuación les presentamos nuestro plan de acción de gobierno...

Borrador de trabajo. Versión (8 Mayo 2007) iconPrograma versión Alumno de

Borrador de trabajo. Versión (8 Mayo 2007) icon1988 Versión original en ingles

Borrador de trabajo. Versión (8 Mayo 2007) iconOpen Game License Version 0a

Borrador de trabajo. Versión (8 Mayo 2007) iconPrograma Madre. Versión preliminar nº 1




Todos los derechos reservados. Copyright © 2019
contactos
b.se-todo.com